Utilize este identificador para referenciar este registo: https://hdl.handle.net/10216/118200
Registo completo
Campo DCValorIdioma
dc.creatorLoureiro, I-
dc.creatorFaria, J-
dc.creatorSantarem, N-
dc.creatorSmith, TK-
dc.creatorTavares, J-
dc.creatorCordeiro-da-Silva, A-
dc.date.accessioned2019-01-08T09:55:10Z-
dc.date.available2019-01-08T09:55:10Z-
dc.date.issued2018-
dc.identifier.issn0929-8673-
dc.identifier.urihttps://repositorio-aberto.up.pt/handle/10216/118200-
dc.description.abstractThe trypanosomatids, Trypanosoma brucei, Trypanosoma cruzi and Leishmania spp, are causative agents of important human diseases such African sleeping sickness, Chagas' disease and Leishmaniasis, respectively. The high impact of these diseases on human health and economy worldwide, the unsatisfactory available chemotherapeutic options and the absence of human effective vaccines, strongly justifies the search for new drugs. The pentose phosphate pathway has been proposed to be a viable strategy to defeat several infectious diseases, including those from trypanosomatids, as it includes an oxidative branch, important in the maintenance of cell redox homeostasis, and a non-oxidative branch in which ribose 5-phosphate and erythrose 4-phosphate, precursors of nucleic acids and aromatic amino acids, are produced. This review provides an overview of the available chemotherapeutic options against these diseases and discusses the potential of genetically validated enzymes from the pentose phosphate pathway of trypanosomatids to be explored as potential drug targets.-
dc.description.sponsorshipThis article is a result of the projects NORTE-01-0145-FEDER-000012, supported by Norte Portugal Regional Operational Programme (NORTE 2020), under the PORTUGAL 2020 Partnership Agreement, through the European Regional Development Fund (ERDF) and from the European Community's Seventh Framework Programme under grant agreements No. 602773 (Project KINDRED). JT is an Investigator FCT funded by National funds through FCT and co-funded through European Social Fund within the Human Potential Operating Programme.-
dc.language.isoeng-
dc.publisherBentham Science Publishers-
dc.relationinfo:eu-repo/grantAgreement/EC/FP7/602773/EU-
dc.relation.ispartofCurrent medicinal chemistry, vol. 25(39), p. 5239 - 5265-
dc.rightsembargoedAccess-
dc.subjectDrug targets-
dc.subjectPentose phosphate pathway-
dc.subjectTreatment-
dc.subjectTrypanosomatids-
dc.titlePotential drug targets in the pentose phosphate pathway of trypanosomatids-
dc.typeArtigo em Revista Científica Internacional-
dc.date.embargo2019-12-31-
dc.contributor.uportoInstituto de Investigação e Inovação em Saúde-
dc.identifier.doi10.2174/0929867325666171206094752-
dc.relation.publisherversionhttp://www.eurekaselect.com/158108/article-
Aparece nas coleções:I3S - Artigo em Revista Científica Internacional

Ficheiros deste registo:
Ficheiro Descrição TamanhoFormato 
Loureiro2017.pdf966.7 kBAdobe PDFThumbnail
Ver/Abrir


Todos os registos no repositório estão protegidos por leis de copyright, com todos os direitos reservados.